175 related articles for article (PubMed ID: 35618441)
21. Evaluating avalglucosidase alfa for the management of late-onset Pompe disease.
Angelini C
Expert Rev Neurother; 2024 Mar; 24(3):259-266. PubMed ID: 38261315
[TBL] [Abstract][Full Text] [Related]
22. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.
Strothotte S; Strigl-Pill N; Grunert B; Kornblum C; Eger K; Wessig C; Deschauer M; Breunig F; Glocker FX; Vielhaber S; Brejova A; Hilz M; Reiners K; Müller-Felber W; Mengel E; Spranger M; Schoser B
J Neurol; 2010 Jan; 257(1):91-7. PubMed ID: 19649685
[TBL] [Abstract][Full Text] [Related]
23. Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease.
Boentert M; Berger KI; Díaz-Manera J; Dimachkie MM; Hamed A; Riou França L; Thibault N; Shukla P; Ishak J; Caro JJ
Orphanet J Rare Dis; 2024 Jan; 19(1):14. PubMed ID: 38216959
[TBL] [Abstract][Full Text] [Related]
24. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa.
van der Ploeg AT; Barohn R; Carlson L; Charrow J; Clemens PR; Hopkin RJ; Kishnani PS; Laforêt P; Morgan C; Nations S; Pestronk A; Plotkin H; Rosenbloom BE; Sims KB; Tsao E
Mol Genet Metab; 2012 Nov; 107(3):456-61. PubMed ID: 23031366
[TBL] [Abstract][Full Text] [Related]
25. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
[TBL] [Abstract][Full Text] [Related]
27. A randomized study of alglucosidase alfa in late-onset Pompe's disease.
van der Ploeg AT; Clemens PR; Corzo D; Escolar DM; Florence J; Groeneveld GJ; Herson S; Kishnani PS; Laforet P; Lake SL; Lange DJ; Leshner RT; Mayhew JE; Morgan C; Nozaki K; Park DJ; Pestronk A; Rosenbloom B; Skrinar A; van Capelle CI; van der Beek NA; Wasserstein M; Zivkovic SA
N Engl J Med; 2010 Apr; 362(15):1396-406. PubMed ID: 20393176
[TBL] [Abstract][Full Text] [Related]
28. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
Chen HA; Hsu RH; Fang CY; Desai AK; Lee NC; Hwu WL; Tsai FJ; Kishnani PS; Chien YH
Front Immunol; 2024; 15():1336599. PubMed ID: 38715621
[TBL] [Abstract][Full Text] [Related]
29. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.
Semplicini C; De Antonio M; Taouagh N; Béhin A; Bouhour F; Echaniz-Laguna A; Magot A; Nadaj-Pakleza A; Orlikowski D; Sacconi S; Salort-Campana E; Solé G; Tard C; Zagnoli F; Hogrel JY; Hamroun D; Laforêt P;
J Inherit Metab Dis; 2020 Nov; 43(6):1219-1231. PubMed ID: 32515844
[TBL] [Abstract][Full Text] [Related]
30. Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group.
Filosto M; Cotti Piccinelli S; Ravaglia S; Servidei S; Moggio M; Musumeci O; Donati MA; Pegoraro E; Di Muzio A; Maggi L; Tonin P; Marrosu G; Sancricca C; Lerario A; Sacchini M; Semplicini C; Bozzoni V; Telese R; Bonanno S; Piras R; Maioli MA; Ricci G; Vercelli L; Galvagni A; Gallo Cassarino S; Caria F; Mongini T; Siciliano G; Padovani A; Toscano A
Adv Ther; 2019 May; 36(5):1177-1189. PubMed ID: 30879255
[TBL] [Abstract][Full Text] [Related]
31. Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort.
Byrne BJ; Colan SD; Kishnani PS; Foster MC; Sparks SE; Gibson JB; An Haack K; Stockton DW; Peña LDM; Hahn SH; Johnson J; Tanpaiboon PX; Leslie ND; Kronn D; Hillman RE; Wang RY;
Cardiol Young; 2022 Mar; 32(3):364-373. PubMed ID: 34420548
[TBL] [Abstract][Full Text] [Related]
32. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
[TBL] [Abstract][Full Text] [Related]
33. 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy.
Regnery C; Kornblum C; Hanisch F; Vielhaber S; Strigl-Pill N; Grunert B; Müller-Felber W; Glocker FX; Spranger M; Deschauer M; Mengel E; Schoser B
J Inherit Metab Dis; 2012 Sep; 35(5):837-45. PubMed ID: 22290025
[TBL] [Abstract][Full Text] [Related]
34. Population Pharmacokinetic Modeling and Determination of Individual Exposure to Avalglucosidase Alfa in Adolescent and Adult Patients With Late-Onset Pompe Disease: Analysis of Pooled Data From Phase I to III Clinical Trials.
Tuffal G; Tiraboschi G; Hurbin F; Boittet P; Palmer R; Martinez JM; Fabre D
Ther Drug Monit; 2023 Oct; 45(5):644-652. PubMed ID: 37556417
[TBL] [Abstract][Full Text] [Related]
35. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review.
Toscano A; Schoser B
J Neurol; 2013 Apr; 260(4):951-9. PubMed ID: 22926164
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.
Nicolino M; Byrne B; Wraith JE; Leslie N; Mandel H; Freyer DR; Arnold GL; Pivnick EK; Ottinger CJ; Robinson PH; Loo JC; Smitka M; Jardine P; Tatò L; Chabrol B; McCandless S; Kimura S; Mehta L; Bali D; Skrinar A; Morgan C; Rangachari L; Corzo D; Kishnani PS
Genet Med; 2009 Mar; 11(3):210-9. PubMed ID: 19287243
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease.
Tiraboschi G; Marchionni D; Tuffal G; Fabre D; Martinez JM; Haack KA; Miossec P; Kittner B; Daba N; Hurbin F
J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):461-474. PubMed ID: 37535240
[TBL] [Abstract][Full Text] [Related]
38. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.
Stockton DW; Kishnani P; van der Ploeg A; Llerena J; Boentert M; Roberts M; Byrne BJ; Araujo R; Maruti SS; Thibault N; Verhulst K; Berger KI
J Neurol; 2020 Oct; 267(10):3038-3053. PubMed ID: 32524257
[TBL] [Abstract][Full Text] [Related]
39. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F
Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922
[TBL] [Abstract][Full Text] [Related]
40. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
